NCT05916287 FAMILY INHERITANCE, GENE-GENE AND GENE-ENVIRONMENT INTERACTIONS IN THE FIELD OF CARDIOVASCULAR AND RENAL DISEASES. Fifth Visit of the STANISLAS Cohort
| NCT ID | NCT05916287 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Central Hospital, Nancy, France |
| Condition | Cardiovascular Diseases |
| Study Type | INTERVENTIONAL |
| Enrollment | 3,000 participants |
| Start Date | 2023-07-13 |
| Primary Completion | 2027-07-13 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 3,000 participants in total. It began in 2023-07-13 with a primary completion date of 2027-07-13.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The Stanislas Cohort is a monocentric familial longitudinal cohort originally comprised of 1006 families consisting of two parents and at least two biological children and deemed healthy, recruited in 1993-1995 at the Centre for Preventive Medicine of Nancy. This cohort was established with the primary objective of investigating gene-gene and gene-environment interactions in the field of cardiovascular diseases. The 5th visit of the STANISLAS Cohort will allow a better evaluation of the cardiovascular ageing of the population and the transition toward cardiovascular or renal diseases in relation with their genetic profile and environment.
Eligibility Criteria
Inclusion Criteria: * aged over 18 * Person who participated in the Stanislas Cohort * Person affiliated to a social security scheme or beneficiary of such a scheme * Person having received complete information on the organization of the research and having signed an informed consent Exclusion Criteria: * Persons deprived of their liberty by a judicial or administrative decision, persons undergoing psychiatric treatment under Articles L. 3212-1 and L. 3213-1 * Person referred to in Articles L. 1121-5, L. 1121-7 and L1121-8 of the Public Health Code: * Pregnant woman, parturient or nursing mother * Adult person subject to a legal protection measure (guardianship, curatorship, safeguard of justice) * Person of full age unable to express consent
Contact & Investigator
Nicolas Girerd, MD, PhD
PRINCIPAL INVESTIGATOR
Centre d'Investigation Clinique 1433 module Plurithématique - CHRU Nancy
Frequently Asked Questions
Who can join the NCT05916287 clinical trial?
This trial is open to participants of all sexes, studying Cardiovascular Diseases. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05916287 currently recruiting?
Yes, NCT05916287 is actively recruiting participants. Visit ClinicalTrials.gov or contact Central Hospital, Nancy, France to inquire about joining.
Where is the NCT05916287 trial being conducted?
This trial is being conducted at Vandœuvre-lès-Nancy, France.
Who is sponsoring the NCT05916287 clinical trial?
NCT05916287 is sponsored by Central Hospital, Nancy, France. The principal investigator is Nicolas Girerd, MD, PhD at Centre d'Investigation Clinique 1433 module Plurithématique - CHRU Nancy. The trial plans to enroll 3,000 participants.